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Introduction 
Pulmonary veno-occlusive disease 
(PVOD) is a rare cause of pulmonary 
arterial hypertension (PAH).1,2 Despite 
being described over 70 years ago, PVOD is 
poorly understood and difficult to diagnose.  
PVOD is associated with connective tissue 
disorders, bone marrow transplantation, 
infection, sarcoidosis, and exposure to 
chemotherapeutic agents including mito-
mycin, bleomycin, and carmustine.1 It is 
characterized by intimal and medial fibrosis 
of the pulmonary venules and veins of the 
lobular septa. We present a case of a patient 
with PVOD receiving mitomycin C for the 
treatment of breast cancer. 
 
Case Report 
A 73-year-old female presented with 
progressive dyspnea over six weeks. She 
had a twelve-year history of breast cancer 
treated with mastectomy, radiation, and 
multiple chemotherapeutic regimens in-
cluding mitomycin. She also had a history of 
chronic obstructive pulmonary disease, 
trastuzumab-induced cardiomyopathy, and 
arthritis.  
She was admitted for congestive heart 
failure (CHF) with hypoxemia, diffuse 
pulmonary infiltrates, and bilateral pleural 
effusions. She was diuresed and symp-
tomatically improved. She was discharged 
home on three liters oxygen. However, her 
symptoms worsened despite diuresis and she 
presented again with progressive hypoxemia  
 
 
on her discharge oxygen. Her chest x-ray 
revealed diffuse bilateral infiltrates similar 
to her prior presentation.  
On examination, she was afebrile with 
tachycardia, tachypnea, and oxygen 
saturation of 88% on three liters. 
Auscultation of the chest revealed bibasilar 
rales, but no jugular venous distension or 
peripheral edema was noted. She had 
bilateral Bouchard and Heberden’s nodes 
with ulnar deviation of her hands. Her 
laboratory data did not reveal leukocytosis.  
A viral respiratory panel was negative and 
renal function was preserved. 
On admission, a work-up of an 
alternative diagnosis to CHF ensued. A CT 
of the chest was performed (Figure 1). An 
echocardiogram confirmed normal chamber 
dimensions and systolic function with 
elevated pulmonary artery pressures. A right 
heart catheterization was performed (Table 
1). The radiographic imaging combined with 
the pulmonary hypertension on right heart 
catheterization and exposure to mitomycin 
made the diagnosis of PVOD highly 
suspicious. Given her pulmonary hyper-
tension and hypoxic respiratory failure, the 
risk of open lung biopsy outweighed 
potential benefits. She was treated with 
steroids and sildenafil, but eventually 
succumbed to her disease within three 
months of diagnosis.   
A limited autopsy revealed intimal and 
medial fibrosis of septal veins consistent 
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with PVOD (Figure 2). There also was 
arteriolarization of pulmonary venules, some 
of which contained organized or recanalized 
thrombi. The adjacent lung parenchyma 
showed fibrosis with hemosiderosis with 
calcium encrustation. The pulmonary 
arteries and arterioles had thickened walls 
consistent with moderate pulmonary hyper-
tension. 
 
 
Figure 1. Small bilateral pleural effusions, 
right greater than left, was seen on CT of the 
chest with contrast. Patchy ground glass 
opacities were observed throughout the 
lungs bilaterally with upper lobe pre-
dominance. Interlobular septal prominence 
and mild dependent atelectasis also were 
noted. 
 
 
Table 1. Right-sided cardiac catheterization 
measurements. 
Systolic pulmonary artery 
pressure 
56 mmHg 
Diastolic  pulmonary artery 
pressure 
29 mmHg 
Mean pulmonary artery 
pressure 
38 mmHg 
Pulmonary capillary wedge 
pressure 
11 mmHg 
Transpulmonary pressure 
gradient 
27 mmHg 
Pulmonary vascular 
resistance  
7.8 wood 
units 
 
 
 
Figure 2. Pulmonary changes seen at autopsy: (A) Intimal and medial fibrosis of a septal 
pulmonary vein was observed. Fibrosis with bluish calcium encrustation and hemosiderin laden 
macrophages in the alveoli are seen adjacent to the vein. (B) Arteriole (A) is observed with a 
thickened wall and a narrowed lumen. Venule (V) has a recanalized thrombus in the lumen and 
thickened wall consistent with arteriolarization seen in PVOD. (Hematoxylin and eosin, (A) 
x160; (B) x220). 
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Discussion 
The patient described above was on 
multiple anti-neoplastic regimens over a 
decade, but her symptoms started after 
receiving the fifth cycle of mitomycin 
therapy. Okuno et al.3 described a range of 2 
to 5 cycles of mitomycin therapy before 
development of PVOD. Definitive diagnosis 
of PVOD requires lung biopsy which can be 
risky in patients with severe pulmonary 
hypertension and hypoxemia.4 The majority 
of cases are diagnosed clinically based on 
radiographic features and excluding other 
causes of PAH. The presence of two or three 
radiological abnormalities including lymph 
node enlargement, thickened septal lines, 
and centrilobular ground-glass opacities had 
a sensitivity of 75% and a specificity of 
84.6% for the detection of PVOD.2 The 
imaging in this case was classic for PVOD 
and autopsy confirmed the clinical 
diagnosis.4  
Our patient had a long history of 
arthritis, but no formal diagnosis of 
rheumatoid arthritis. Interestingly, her 
rheumatoid factor and anti-cyclic citrull-
inated peptide levels were elevated, and 
perhaps connective tissue disease could be 
another factor contributing to development 
of  PVOD.5   This  possibility  could  not  be  
 
ruled out completely by autopsy as PVOD 
secondary to mitomycin and connective 
tissue disease have identical pathologic 
findings. Based on the temporal relationship 
in this case, mitomycin seems to be the 
likely etiology.  
Treatment remains a challenge as 
exposure to pulmonary vasodilators used to 
treat PAH may precipitate acute pulmonary 
edema in patients with PVOD. However, 
phospodiesterase-5 inhibitors have been 
used successfully to treat PVOD, but no 
prospective studies exist and they should be 
prescribed only by someone with expertise 
in pulmonary hypertension and PVOD 
management. The use of steroids in PVOD 
has mixed results and lung transplantation is 
the definitive treatment.2  
PVOD should be considered in cancer 
patients with hypoxia, diffuse infiltrates, 
pulmonary hypertension, and exposure to 
mitomycin. It is equally important to 
differentiate PVOD from other causes of 
PAH as standard therapy for PAH can be 
detrimental in PVOD. Although not an 
option for our patient, early diagnosis may 
allow for lung transplantation in a patient 
without contraindications to transplant. 
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